Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not representative of patients in clinical practice: The netherlands stroke survey

Stroke

Volumn 40, Issue 8, 2009, Pages 2662-2668

  Maasland, Lisette ^a,b   Van Oostenbrugge, Robert J ^c   Franke, Cees F ^d   Scholte Op Reimer, Wilma J M ^a   Koudstaal, Peter J ^a   Dippel, Diederik W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Bethesda Hospital   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

Author keywords

Antiplatelet drugs; RCT; Survey

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TRIFLUSAL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; DATA COLLECTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; STROKE;

EID: 68749089916     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.551812     Document Type: Article

References (28)

1. Truelsen T, Mahonen M, Tolonen H, Asplund K, Bonita R, Vanuzzo D. Trends in stroke and coronary heart disease in the WHO MONICA Project. Stroke. 2003;34:1346-1352.
2. van Wijk I, Kappelle LJ, van GJ, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098-2104.
3. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255.
4. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673.
5. O'Donnell MJ, Hankey GJ, Eikelboom JW. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. Stroke. 2008;39:1638-1646.
6. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39:1358-1363.
7. Howard SC, Algra A, Warlow CP, Rothwell PM. Potential consequences for recruitment, power, and external validity of requirements for additional risk factors for eligibility in randomized controlled trials in secondary prevention of stroke. Stroke. 2006;37:209-215.
8. Scholte Op Reimer WJ, Dippel DW, Franke CL, van Oostenbrugge RJ, de Jong G, Hoeks S, Simoons ML. Quality of hospital and outpatient care after stroke or transient ischemic attack: insights from a stroke survey in The Netherlands. Stroke. 2006;37:1844-1849.
9. Lingsma HF, Dippel DW, Hoeks S, Steyerberg EW, Franke CL, van Oostenbrugge RJ, de JG, Simoons ML, Scholte op Reimer WJ. Variation between hospitals in patient outcome after stroke is only partly explained by differences in quality of care. Data from the Netherlands Stroke Survey. J Neurol Neurosurg Psychiatry. 2008;79:888-894.
10. CAPRIE Study Group. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
11. De Schryver EL. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovasc Dis. 2000;10:147-150.
12. De Schryver EL. ESPRIT. Protocol change. Cerebrovasc Dis. 2001;11:286.
13. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
14. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc Dis. 2004;17:253-261.
15. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23:368-380.
16. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of Triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke. 2003;34:840-848.
17. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
18. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De KJ, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
19. Mant J, McManus RJ, Hare R. Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study. BMJ. 2006;332:635-637.
20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
21. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet. 2005;365:82-93.
22. Charlson ME, Horwitz RI. Applying results of randomised trials to clinical practice: impact of losses before randomisation. BMJ (Clin Res Ed). 1984;289:1281-1284.
23. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
24. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354: 1706-1717.
25. Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de WF, Willerson JT, Chan R, Samuels R, Ilson B, Granett J. Design of the Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial. Am Heart J. 2000;139: 927-933.
26. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de WF, Sigmon K, Pieper K, Vallee M, Willerson JT. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406.
27. Rothwell PM. Lessons from MATCH for future randomised trials in secondary prevention of stroke. Lancet. 2004;364:305-307.
28. Halkes PH, Gray LJ, Bath PM, Diener HC, Guiraud-Chaumeil B, Yatsu FM, Algra A. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry. 2008;79:1218-1223.